Pfizer: Integrin beta-6 (IB6) Sigvotatug Vedotin (SV) Translational and Pre-Clinical Research RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Thursday 13th, March 2025
External Deadline: Thursday 20th, March 2025
Description
Pfizer Global Medical Grants & Partnerships (GMGP) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMGP competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Date RFP Issued: January 22, 2025
Geographic Scope: Global
Clinical Area: Non-Small Cell Lung Cancer (NSCLC)
Link to full RFP: Integrin beta-6 (IB6) Sigvotatug Vedotin (SV) Translational and Pre-Clinical Research
Application Due Date: March 20, 2025
Specific Area of Interest: The intent of this RFP is to support non-interventional Investigator Sponsored Research projects that will advance the understanding of IB6 patterns of expression and clinical outcomes in NSCLC or explore sigvotatug vedotin’s preclinical activity.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jacqueline Waldrop (Jacqueline.Waldrop@Pfizer.com).